MPR

FDA Approves New Regimen for Cisplatin-Ineligible MIBC Patients

Overall survival data showed a 50% reduction in the risk of death with the regimen compared with surgery alone.

U.S. FDA Approves PADCEV(R) plus Keytruda(R) for Certain Patients with Bladder Cancer

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...
Le Lézard

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin ...